PMID- 20025479
OWN - NLM
STAT- MEDLINE
DCOM- 20100225
LR  - 20151119
IS  - 1465-3931 (Electronic)
IS  - 0031-3025 (Linking)
VI  - 42
IP  - 1
DP  - 2010 Jan
TI  - Annexin-I overexpression is associated with tumour progression and independently 
      predicts inferior disease-specific and metastasis-free survival in urinary 
      bladder urothelial carcinoma.
PG  - 43-9
LID - 10.3109/00313020903434405 [doi]
AB  - AIMS: In our previous studies, comparative proteomics and immunohistochemistry 
      (IHC) demonstrated that annexin-I (ANXA1) is up-regulated in high grade urinary 
      bladder urothelial carcinoma (UBUC) as compared to non-high grade carcinomas. 
      However, the small sample size prohibited further correlation of ANXA1 expression 
      to tumour progression. Therefore, in the present study, 81 primary localised UBUC 
      specimens of various grades and primary tumour (pT) status were examined for 
      ANXA1 expression to further confirm the proteomics data and to clarify the 
      relevance of ANXA1 expression level to the prognosis of UBUC. METHODS: IHC was 
      implemented to investigate ANXA1 protein expression in 81 primary localised UBUC 
      specimens. The association of ANXA1 expression with tumour progression and 
      prognosis was analysed. RESULTS: Our data demonstrated that the ANXA1 expression 
      level was strongly associated with an escalated pT status (p < 0.001) and a 
      higher histological grade (p < 0.001), suggesting that ANXA1 might be related to 
      tumour progression. Moreover, at the univariate level, ANXA1 overexpression, 
      along with higher pT status and histological grade, significantly predicted 
      disease-specific survival (DSS) and metastasis-free survival (MFS). More 
      importantly, multivariate analyses revealed that the association of ANXA1 
      overexpression and prognosis remained significant for both DSS and MFS. 
      CONCLUSION: The above results reinforced the comparative proteomics results and 
      confirmed the prognostic role of ANXA1 in UBUC.
FAU - Li, Chien-Feng
AU  - Li CF
AD  - Department of Pathology, Chi-Mei Medical Center, Tainan, Taiwan.
FAU - Shen, Kun-Hung
AU  - Shen KH
FAU - Huang, Li-Chien
AU  - Huang LC
FAU - Huang, Hsuan-Ying
AU  - Huang HY
FAU - Wang, Yu-Hui
AU  - Wang YH
FAU - Wu, Ting-Feng
AU  - Wu TF
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Pathology
JT  - Pathology
JID - 0175411
RN  - 0 (Annexin A1)
RN  - 0 (Biomarkers, Tumor)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Annexin A1/*metabolism
MH  - Biomarkers, Tumor/metabolism
MH  - Carcinoma, Transitional Cell/*metabolism/mortality/secondary
MH  - Cystectomy
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Female
MH  - Fluorescent Antibody Technique, Direct
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Proteomics
MH  - Survival Rate
MH  - Taiwan/epidemiology
MH  - Urinary Bladder Neoplasms/*metabolism/mortality/pathology
EDAT- 2009/12/23 06:00
MHDA- 2010/02/26 06:00
CRDT- 2009/12/23 06:00
PHST- 2009/12/23 06:00 [entrez]
PHST- 2009/12/23 06:00 [pubmed]
PHST- 2010/02/26 06:00 [medline]
AID - 10.3109/00313020903434405 [doi]
PST - ppublish
SO  - Pathology. 2010 Jan;42(1):43-9. doi: 10.3109/00313020903434405.